The index patient, an 18-year-old woman, born as the second of 2 children to consanguineous parents, reported weakness and dyspnea from early childhood. Pregnancy and birth were normal, but postpartum, she had dysphagia and was tube fed. Early motor milestones were delayed, with independent ambulation achieved at age 2.25 years and inability to lift her head from a supine position until age 3 years. She experienced improvement in her condition throughout childhood, but still had reduced walking distance (2.5 km), difficulty lifting heavy objects, and experienced patella luxations.
On examination, the patient is 150 cm tall and has a dolichocephalic head shape and elbow hypermobility (figure 1A). Strength testing showed diffuse muscle force reduction at Medical Research Council (MRC) grade 4, with no distal/proximal gradient, and axial weakness. Spirometry showed normal forced vital capacity (FVC) (88%) and forced expiratory volume (FEV1) (96%).
Creatine kinase (CK) levels and neurophysiologic findings were normal. Replacement of muscle by fat on MRI was pronounced in gluteus maximus and hamstring muscles (figure 1B). Muscle biopsy, at age 4 years, displayed myopathic features with varying fiber size, increased number of internalized nuclei, atrophic fibers, and endomysial fibrosis and fat infiltration.
Next-generation sequencing revealed homozygosity for a previously described missense variant in SCN4A (NM_000334.4: c.3425G>A(p.Arg.1142Gln)), 2 confirmed through Sanger sequencing, and was deemed to be pathogenic by 6 prediction tools. Parents were heterozygous for the variant.
The 22-year-old sister of the index patient was also homozygous for Arg1142Gln. She had milder muscular complaints than her sister, which included difficulties lifting her head when lying down, exertional shortness of breath, and poor cycling capacity since childhood. She had elbow joint hypermobility like her sister. Her motor milestones were normal. Strength testing 
Functional assessment of the Arg1142Gln (R1142Q) variant in human embryonic kidney 293 (HEK293) cells revealed partial loss-of-function effects (figure 2), as previously reported in SCN4A-related congenital myopathy.
1,2 Na V 1.4 R1142Q peak current density was significantly lower than wild type (WT) (WT: 106.4 ± 12.4 pA/pF, R1142Q: −39.0 ± 6.4 pA/pF at 5 mV, figure 2, A and B) , and the voltage dependence of channel activation was significantly changed (figure 2, C and D).
Variants in SCN4A were originally linked to congenital myasthenia, 3, 4 but recently, also to severe fetal hypokinesia and early lethality 1 and to sudden infant death syndrome. 5 A strikingly milder phenotype of "classical" congenital myopathy has been described in 6 patients with SCN4A variants in a recessive pattern, only 3 of whom were adults (aged 18-35 years old).
1,2 Our 18-year-old index patient exhibited a phenotype similar to that previously reported, 1 while her 20-year-old sister was only marginally affected. Our index patient's characteristic muscle MRI findings were similar to 4 other patients with SCN4A mutations, including 2 brothers, compound heterozygous for c.3425G>A(p.Arg1142Gln) and another missense variant c.1123T>C (p.Cys375Arg).
1,2 The brothers, unlike our patients, had elongated faces, ptosis, facial weakness, scoliosis, and elevated CK. 2 We speculate whether homozygosity for the p.Arg1142Gln variant conferred the milder phenotype observed in our patients. The present report expands our knowledge regarding SCN4A-related congenital myopathy in adulthood and underscores that the phenotype of this disorder may vary considerably, even within members of the same family, as in other recessive channelopathies affecting muscles. 6 Author contributions C.K. Sloth: drafted the manuscript and performed administrative work. F. Denti: tested the effect of the SCN4A mutation in a cell line. N. Schmitt: tested the effect of the SCN4A mutation in a cell line, interpreted data, revised the manuscript, and drafted figures. B.H. Bentzen: tested the effect of the SCN4A mutation in a cell line. C. Fagerberg: in charge of DNA-testing of the 2 sisters and revised the manuscript.
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